Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy")

Carla L. Busceti, Francesca Biagioni, Barbara Riozzi, Giuseppe Battaglia, Marianna Storto, Carlo Cinque, Gemma Molinaro, Roberto Gradini, Andrea Caricasole, Anna Maria Canudas, Valeria Bruno, Ferdinando Nicoletti, Francesco Fornai

Research output: Contribution to journalArticle

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) ("Ecstasy") produces neurotoxic effects, which result into an impairment of learning and memory and other neurological dysfunctions. We examined whether MDMA induces increases in tau protein phosphorylation, which are typically associated with Alzheimer's disease and other chronic neurodegenerative disorders. We injected mice with MDMA at cumulative doses of 10-50 mg/kg intraperitoneally, which are approximately equivalent to doses generally consumed by humans. MDMA enhanced the formation of reactive oxygen species and induced reactive gliosis in the hippocampus, without histological evidence of neuronal loss. An acute or 6 d treatment with MDMA increased tau protein phosphorylation in the hippocampus, revealed by both anti-phospho(Ser404)-tau and paired helical filament-1 antibodies. This increase was restricted to the CA2/CA3 subfields and lasted 1 and 7 d after acute and repeated MDMA treatment, respectively. Tau protein was phosphorylated as a result of two nonredundant mechanisms: (1) inhibition of the canonical Wnt (wingless-type MMTV integration site family) pathway, with ensuing activation of glycogen synthase kinase-3β; and (2) activation of type-5 cyclin-dependent kinase (Cdk5). MDMA induced the expression of the Wnt antagonist, Dickkopf-1, and the expression of the Cdk5-activating protein, p25. In addition, the increase in tau phosphorylation was attenuated by strategies that rescued the Wnt pathway or inhibited Cdk5. Finally, an impairment in hippocampus-dependent spatial learning was induced by doses of MDMA that increased tau phosphorylation, although the impairment outlasted this biochemical event. We conclude that tau hyperphosphorylation in the hippocampus may contribute to the impairment of learning and memory associated with MDMA abuse.

Original languageEnglish
Pages (from-to)3234-3245
Number of pages12
JournalJournal of Neuroscience
Volume28
Issue number12
DOIs
Publication statusPublished - Mar 19 2008

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Hippocampus
Phosphorylation
tau Proteins
Cyclin-Dependent Kinase 5
Learning
Glycogen Synthase Kinase 3
Wnt Signaling Pathway
Gliosis
Neurodegenerative Diseases
Reactive Oxygen Species
Alzheimer Disease

Keywords

  • Cdk5
  • Dickkopf-1
  • Hippocampus
  • MDMA
  • Neurotoxicity
  • Tau phosphorylation

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy"). / Busceti, Carla L.; Biagioni, Francesca; Riozzi, Barbara; Battaglia, Giuseppe; Storto, Marianna; Cinque, Carlo; Molinaro, Gemma; Gradini, Roberto; Caricasole, Andrea; Canudas, Anna Maria; Bruno, Valeria; Nicoletti, Ferdinando; Fornai, Francesco.

In: Journal of Neuroscience, Vol. 28, No. 12, 19.03.2008, p. 3234-3245.

Research output: Contribution to journalArticle

@article{80cd02577feb4fae87324b2977f4839d,
title = "Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ({"}Ecstasy{"})",
abstract = "3,4-Methylenedioxymethamphetamine (MDMA) ({"}Ecstasy{"}) produces neurotoxic effects, which result into an impairment of learning and memory and other neurological dysfunctions. We examined whether MDMA induces increases in tau protein phosphorylation, which are typically associated with Alzheimer's disease and other chronic neurodegenerative disorders. We injected mice with MDMA at cumulative doses of 10-50 mg/kg intraperitoneally, which are approximately equivalent to doses generally consumed by humans. MDMA enhanced the formation of reactive oxygen species and induced reactive gliosis in the hippocampus, without histological evidence of neuronal loss. An acute or 6 d treatment with MDMA increased tau protein phosphorylation in the hippocampus, revealed by both anti-phospho(Ser404)-tau and paired helical filament-1 antibodies. This increase was restricted to the CA2/CA3 subfields and lasted 1 and 7 d after acute and repeated MDMA treatment, respectively. Tau protein was phosphorylated as a result of two nonredundant mechanisms: (1) inhibition of the canonical Wnt (wingless-type MMTV integration site family) pathway, with ensuing activation of glycogen synthase kinase-3β; and (2) activation of type-5 cyclin-dependent kinase (Cdk5). MDMA induced the expression of the Wnt antagonist, Dickkopf-1, and the expression of the Cdk5-activating protein, p25. In addition, the increase in tau phosphorylation was attenuated by strategies that rescued the Wnt pathway or inhibited Cdk5. Finally, an impairment in hippocampus-dependent spatial learning was induced by doses of MDMA that increased tau phosphorylation, although the impairment outlasted this biochemical event. We conclude that tau hyperphosphorylation in the hippocampus may contribute to the impairment of learning and memory associated with MDMA abuse.",
keywords = "Cdk5, Dickkopf-1, Hippocampus, MDMA, Neurotoxicity, Tau phosphorylation",
author = "Busceti, {Carla L.} and Francesca Biagioni and Barbara Riozzi and Giuseppe Battaglia and Marianna Storto and Carlo Cinque and Gemma Molinaro and Roberto Gradini and Andrea Caricasole and Canudas, {Anna Maria} and Valeria Bruno and Ferdinando Nicoletti and Francesco Fornai",
year = "2008",
month = "3",
day = "19",
doi = "10.1523/JNEUROSCI.0159-08.2008",
language = "English",
volume = "28",
pages = "3234--3245",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "12",

}

TY - JOUR

T1 - Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy")

AU - Busceti, Carla L.

AU - Biagioni, Francesca

AU - Riozzi, Barbara

AU - Battaglia, Giuseppe

AU - Storto, Marianna

AU - Cinque, Carlo

AU - Molinaro, Gemma

AU - Gradini, Roberto

AU - Caricasole, Andrea

AU - Canudas, Anna Maria

AU - Bruno, Valeria

AU - Nicoletti, Ferdinando

AU - Fornai, Francesco

PY - 2008/3/19

Y1 - 2008/3/19

N2 - 3,4-Methylenedioxymethamphetamine (MDMA) ("Ecstasy") produces neurotoxic effects, which result into an impairment of learning and memory and other neurological dysfunctions. We examined whether MDMA induces increases in tau protein phosphorylation, which are typically associated with Alzheimer's disease and other chronic neurodegenerative disorders. We injected mice with MDMA at cumulative doses of 10-50 mg/kg intraperitoneally, which are approximately equivalent to doses generally consumed by humans. MDMA enhanced the formation of reactive oxygen species and induced reactive gliosis in the hippocampus, without histological evidence of neuronal loss. An acute or 6 d treatment with MDMA increased tau protein phosphorylation in the hippocampus, revealed by both anti-phospho(Ser404)-tau and paired helical filament-1 antibodies. This increase was restricted to the CA2/CA3 subfields and lasted 1 and 7 d after acute and repeated MDMA treatment, respectively. Tau protein was phosphorylated as a result of two nonredundant mechanisms: (1) inhibition of the canonical Wnt (wingless-type MMTV integration site family) pathway, with ensuing activation of glycogen synthase kinase-3β; and (2) activation of type-5 cyclin-dependent kinase (Cdk5). MDMA induced the expression of the Wnt antagonist, Dickkopf-1, and the expression of the Cdk5-activating protein, p25. In addition, the increase in tau phosphorylation was attenuated by strategies that rescued the Wnt pathway or inhibited Cdk5. Finally, an impairment in hippocampus-dependent spatial learning was induced by doses of MDMA that increased tau phosphorylation, although the impairment outlasted this biochemical event. We conclude that tau hyperphosphorylation in the hippocampus may contribute to the impairment of learning and memory associated with MDMA abuse.

AB - 3,4-Methylenedioxymethamphetamine (MDMA) ("Ecstasy") produces neurotoxic effects, which result into an impairment of learning and memory and other neurological dysfunctions. We examined whether MDMA induces increases in tau protein phosphorylation, which are typically associated with Alzheimer's disease and other chronic neurodegenerative disorders. We injected mice with MDMA at cumulative doses of 10-50 mg/kg intraperitoneally, which are approximately equivalent to doses generally consumed by humans. MDMA enhanced the formation of reactive oxygen species and induced reactive gliosis in the hippocampus, without histological evidence of neuronal loss. An acute or 6 d treatment with MDMA increased tau protein phosphorylation in the hippocampus, revealed by both anti-phospho(Ser404)-tau and paired helical filament-1 antibodies. This increase was restricted to the CA2/CA3 subfields and lasted 1 and 7 d after acute and repeated MDMA treatment, respectively. Tau protein was phosphorylated as a result of two nonredundant mechanisms: (1) inhibition of the canonical Wnt (wingless-type MMTV integration site family) pathway, with ensuing activation of glycogen synthase kinase-3β; and (2) activation of type-5 cyclin-dependent kinase (Cdk5). MDMA induced the expression of the Wnt antagonist, Dickkopf-1, and the expression of the Cdk5-activating protein, p25. In addition, the increase in tau phosphorylation was attenuated by strategies that rescued the Wnt pathway or inhibited Cdk5. Finally, an impairment in hippocampus-dependent spatial learning was induced by doses of MDMA that increased tau phosphorylation, although the impairment outlasted this biochemical event. We conclude that tau hyperphosphorylation in the hippocampus may contribute to the impairment of learning and memory associated with MDMA abuse.

KW - Cdk5

KW - Dickkopf-1

KW - Hippocampus

KW - MDMA

KW - Neurotoxicity

KW - Tau phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=41149155241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149155241&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.0159-08.2008

DO - 10.1523/JNEUROSCI.0159-08.2008

M3 - Article

C2 - 18354027

AN - SCOPUS:41149155241

VL - 28

SP - 3234

EP - 3245

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 12

ER -